JMP Securities Reiterates Market Outperform Rating for Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “market outperform” rating reaffirmed by research analysts at JMP Securities in a research note issued on Tuesday, Benzinga reports. They currently have a $70.00 price target on the stock. JMP Securities’ price objective would suggest a potential upside of 285.04% from the company’s current price.

Several other equities analysts have also recently issued reports on JSPR. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Tuesday. Royal Bank of Canada lowered their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 14th. Stifel Nicolaus started coverage on shares of Jasper Therapeutics in a report on Thursday, June 27th. They issued a “buy” rating and a $86.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Finally, Evercore ISI restated an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 26th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $74.86.

Jasper Therapeutics Stock Down 0.5 %

NASDAQ:JSPR opened at $18.18 on Tuesday. The company’s 50 day moving average price is $19.00 and its 200-day moving average price is $21.51. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01. The stock has a market cap of $273.86 million, a price-to-earnings ratio of -3.23 and a beta of 2.21.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.12. As a group, sell-side analysts anticipate that Jasper Therapeutics will post -4.16 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of JSPR. Wolff Wiese Magana LLC bought a new stake in Jasper Therapeutics during the third quarter valued at about $59,000. Virtu Financial LLC bought a new position in shares of Jasper Therapeutics in the first quarter worth about $306,000. Rhumbline Advisers purchased a new position in shares of Jasper Therapeutics during the 2nd quarter valued at about $300,000. American Century Companies Inc. grew its stake in shares of Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after acquiring an additional 3,032 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new stake in Jasper Therapeutics in the 1st quarter worth approximately $599,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.